The SGLT2 Inhibitor Empagliflozin Directly Binds Cardiac JNK3, Uncouples c-Jun/c-Fos Signaling, and Confers Cardioprotection in Diabetic Cardiomyopathy
Open Access
- 12 October 2026
- journal article
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunitiesAdvanced Drug Delivery Reviews, 2021
- Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction After Myocardial InfarctionEuropean Journal of Heart Failure, 2019
- Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapyHeart Failure Reviews, 2018
- Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 DiabetesCardiovascular Drugs and Therapy, 2017
- The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effectsDiabetologia, 2017
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbitsDiabetologia, 2016
- Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury following ischemia/reperfusionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisalDiabetes & Metabolism, 2014
- Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potentialBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004
- Activation of c-Jun N-Terminal Kinases and p38-Mitogen-activated Protein Kinases in Human Heart Failure Secondary to Ischaemic Heart DiseaseJournal of Molecular and Cellular Cardiology, 1999